So Deok Lee

Title: So Deok Lee and FLT3 and RET Kinase Inhibitor Innovation.

Introduction

So Deok Lee is an inventor associated with Gwangju, South Korea, and Pelemed Co., Ltd. Her patent work concerns indirubin derivatives designed to inhibit FLT3 and RET kinases, targets relevant to certain diseases, including acute myeloid leukemia.

Latest Patents

Lee is associated with 1 patent: “Indirubin Derivatives Having Heterobicyclic Moieties and the Use Thereof.” The invention describes novel compounds intended to inhibit fms-like tyrosine kinase 3 (FLT3) and rearranged during transfection (RET) kinase activity. The patent presents these compounds as potential agents for preventing or treating diseases associated with mutant FLT3 or mutant RET, particularly acute myeloid leukemia.

Career Highlights

Lee’s listed patent reflects research into targeted kinase inhibition and potential therapeutic applications. Her work is associated with Pelemed Co., Ltd., a company connected to the development of the invention.

Collaborations

The listed coworkers associated with Lee are Soo Yeon Jang and Myung Jin Kim. Their names appear alongside Lee in connection with the patent work.

Conclusion

So Deok Lee’s patent focuses on indirubin-based compounds that may inhibit FLT3 and RET kinases, highlighting a potential approach to addressing diseases such as acute myeloid leukemia.